Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia
Prince Alfred Singh, Medical Officer at Addu Equatorial Hospital (AEH), shared a post on LinkedIn:
“Understanding Antithrombin III Deficiency: A High-Risk Thrombophilia
Antithrombin III (AT III) plays a critical role as the body’s natural anticoagulant – primarily inhibiting thrombin (IIa) and factor Xa to prevent excessive clot formation.
What happens in AT III deficiency?
A reduction in this key inhibitor shifts the hemostatic balance toward thrombosis, making it one of the most clinically significant inherited thrombophilias.
Key Facts:
- Inherited in an autosomal dominant pattern
- Prevalence: approximately 1 in 3,000 individuals
- Strongly associated with recurrent venous thromboembolism (VTE)
- Arterial events are less common but can occur
Risk Perspective:
Compared to other thrombophilias such as Factor V Leiden or Protein C deficiency, AT III deficiency carries one of the highest relative risks for VTE.
Clinical Management Insights:
- Many patients require long-term anticoagulation (e.g., warfarin)
- Heparin resistance can occur due to low AT levels
- In pregnancy: heparin-based therapy is preferred
- Consider AT concentrate in selected high-risk scenarios
Clinical Takeaway:
- Early recognition is essential—especially in patients with:
- Recurrent unexplained VTE
- Strong family history of thrombosis
- Thrombosis at a young age
A tailored, lifelong management strategy can significantly reduce morbidity and prevent life-threatening complications.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 10:24Sara Zalghout: The Little Things That Make ISTH 2026 Special
-
Jul 14, 2026, 10:11Joseph R. Shaw: GAUGE Advances FXa Inhibitor Reversal at ISTH 2026
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation
-
Jul 13, 2026, 22:33ESOC 2026 recordings are now available on eSTEP – European Stroke Organisation
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026